Accuracy of positron emission tomography/computed tomography and clinical assessment in the detection of complete rectal tumor regression after neoadjuvant chemoradiation Long-Term Results of a Prospective Trial (National Clinical Trial 00254683)

Author(s):Show less -

Perez, Rodrigo Oliva ^{[1, 2]} ; Habr-Gama, Angelita ^[1] ; Gama-Rodrigues, Joaquim ^[1] ; Proscurshim, Igor ^[1] ; Sao Juliao, Guilherme Pagin ^[2] ; Lynn, Patricio ^[1] ; Ono, Carla Rachel ^{[3, 4]} ; Campos, Fabio Guilherme ^[2] ; Silva e Sousa, Jr., Afonso Henrique ^[2] ; Imperiale, Antonio Rocco ^[2] ; Nahas, Sergio Carlos ^[2] ; Buchpiguel, Carlos Alberto ^{[3, 4]}

Affiliation

^[1] Angelita & Joaquim Gama Inst, Sao Paulo - Brazil

^[2] Univ Sao Paulo, Sch Med, Colorectal Surg Div, Dept Gastroenterol, Sao Paulo - Brazil

^[3] Univ Sao Paulo, Sch Med, Dept Radiol, Div Nucl Med, Sao Paulo - Brazil

^[4] Hosp Coracao Sao Paulo, Dept Radiol & Nucl Med, Sao Paulo - Brazil

• Document type: Journal article
• Source: Cancer; v. 118, n. 14, p. 3501-3511, JUL 15 2012.
• Web of Science Citations: 66

Abstract

BACKGROUND: Neoadjuvant chemoradiation (CRT) therapy may result in significant tumor regression in patients with rectal cancer. Patients who develop complete tumor regression have been managed by treatment strategies that are alternatives to standard total mesorectal excision. Therefore, assessment of tumor response with positron emission tomography/computed tomography (PET/CT) after neoadjuvant treatment may offer relevant information for the selection of patients to receive alternative treatment strategies. METHODS: Patients with clinical T2 (cT2) through cT4NxM0 rectal adenocarcinoma were included prospectively. Neoadjuvant therapy consisted of 54 grays of radiation and 5-fluorouracil-based chemotherapy. Baseline PET/CT studies were obtained before CRT followed by PET/CT studies at 6 weeks and 12 weeks after the completion of CRT. Clinical assessment was performed at 12 weeks after CRT completion. PET/CT results were compared with clinical and pathologic data. RESULTS: In total, 99 patients were included in the study. Twenty-three patients were complete responders (16 had a complete clinical response, and 7 had a complete pathologic response). The PET/CT response evaluation at 12 weeks indicated that 18 patients had a complete response, and 81 patients had an incomplete response. There were 5 false-negative and 10 false-positive PET/CT results. PET/CT for the detection of residual cancer had 93% sensitivity, 53% specificity, a 73% negative predictive value, an 87% positive predictive value, and 85% accuracy. Clinical assessment alone resulted in an accuracy of 91%. PET/CT information may have detected misdiagnoses made by clinical assessment alone, improving overall accuracy to 96%. CONCLUSIONS: Assessment of tumor response at 12 weeks after CRT completion with PET/CT imaging may provide a useful additional tool with good overall accuracy for the selection of patients who may avoid unnecessary radical resection after achieving a complete clinical response. Cancer 2012;35013511. (C) 2011 American Cancer Society. (AU)